Private Capital Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Private Capital Group’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Buy	+264	New	+$1.45K	﹤0.01%	1766

Other funds holding RYTM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Private Capital Group's RYTM Position: Q2 2022 in Review

Private Capital Group opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2022: 264 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1766 among its holdings.

90 funds tracked by Wall St. Rank hold RYTM as of Q2 2022.

Private Capital Group held 264 shares of Rhythm Pharmaceuticals worth $1K as of Q2 2022.
Rhythm Pharmaceuticals was a new Private Capital Group position in Q2 2022.
Rhythm Pharmaceuticals made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1766 holding.
90 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.